Megan Peacock’s Post

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place In this article, Ben Comer, Chief Editor at Life Science Leader, looks towards next year and discusses manufacturing and supply chain processes with 7 executives in biopharma... Read below to find out what they had to say ⤵ #CDMO #Biopharma #Manufacturing

Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place In this article, Ben Comer, Chief Editor at Life Science Leader, looks towards next year and discusses manufacturing and supply chain processes with 7 executives in biopharma... Read below to find out what they had to say ⤵ #CDMO #Biopharma #Manufacturing

🦸🏻♂️ As part of our ongoing series called "𝐇𝐞𝐫𝐨𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐉𝐨𝐮𝐫𝐧𝐞𝐲," we have delved into the challenges supply chain teams face in emerging 𝐛𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬. Today, we will discuss the disconnect between the upstream and downstream supply groups and how it can impact the success of these companies. 💡We suggest establishing crucial cross-functional teams and creating a detailed plan that maps out processes, workstreams, and timelines. By doing this, a clear picture emerges, making it easier to make strategic decisions. For more information, please visit: https://hubs.li/Q02mVvgw0 #SVA #SVALifeSciences #LifeSciencesIndustry #BiopharmaCompanies #BiopharmaIndustry

In this Life Science Leader article, industry experts share positive and negative forecasts for the upcoming year, addressing concerns such as supply chain issues and advantages including emerging technologies that potentially will propel the industry forward. Omair Ahmed, Chief Operating Officer of Nexus Pharmaceuticals (the recipient of Honorable Mention 2023 FOYA), elaborates on the proactive measures Nexus is presently undertaking to address potential future drug shortages. Read More: https://bit.ly/3RaLYve #DrugManufacturing #Pharma #FOYA24

Join our pharma & lifescience series to gain insights on various topics related to the industry! The next session is tomorrow around supply chain

Despite unforeseen challenges in #biotechnology, maintaining flexibility and resiliency will push a company ahead. In Life Science Leader’s recently published Industry Outlook issue, they discuss a pertinent industry challenge: maintaining efficient manufacturing processes.    Our SVP of Manufacturing and Supply Chain, Roger Bakale, Ph.D. shared his thoughts on the biopharma manufacturing function in 2024, including anticipated challenges and technologies to improve manufacturing efficiency.   Read the article here: https://bit.ly/4acgmht

Check out our latest article published in Pharma Focus Asia where Lyn McNeill – Supply Chain Solutions Manager (JTM) discusses how Just in Time Manufacturing can drastically reduce waste and support sponsors to uphold their responsibility to patients in profit margin. https://hubs.li/Q02yQv7N0

How to ensure consistent product supply of pharma companies in an ever more complex and uncertain environment? Pharma companies are re-shuffling their manufacturing networks to cope with new challenges. They are already transitioning from centralized, cost-optimized #SupplyChains to decentralized, more adaptable models with local #production capabilities.   For companies planning this shift, seeking an external perspective can offer valuable insights into their current #NetworkDesign. Implementing a decentralized approach can enhance supply chain #resilience, operational efficiency, and lay a solid foundation for future growth.   Please take a look at #RolandBerger's three-step framework for pharma businesses: https://lnkd.in/d9nPMh-T   We are happy to exchange with you in more detail on this topic: Stephan Fath Morris Hosseini Thilo Kaltenbach Matthias Bünte

My opinion piece on supply chain and biopharma...